Neopac to Introduce New Eyecare Solution at CPhI 2018

Article

Neopac, provider of high-quality tube packaging, has announced in a press release it will introduce a new eyecare solution at CPhI’s event in Madrid, Spain from Oct. 9–11, 2018.

Neopac, provider of high-quality tube packaging, has announced in a press release it will introduce a new eyecare solution at CPhI’s event in Madrid, Spain from Oct. 9–11, 2018.

The company will present the SteriDrop tube during the event, which offers protection and delivery of preservative-free eye drops. The SteriDrop tube is filled and sealed on sterile tube filling lines and uses Neopac’s patented Polyfoil technology for product protection. 

In combination with an Aptar Pharma ophthalmic squeeze dispenser, the microbiological integrity of the product is assured before, during, and after use. This is possible through the use of a mechanical system, which releases a precisely measured drop when the user squeezes the SteriDrop tube. This system then also prevents any liquid flowing back into the tube, thereby guaranteeing the microbiological integrity of the eye drops and negating the need for preservatives.

Furthermore, the Polyfoil tube barrier protects the eye drop solution from light, air, water vapour diffusion, and migration. This further enhances critical content efficacy and the overall product durability.

“Our new SteriDrop tubes offer an unprecedented combination of product protection and ease of use for eye drop users,” said Martina Christiansen, head of Sales and Marketing Pharma of Hoffmann Neopac, in a press release. “More and more consumers are opting for preservative-free eyecare solutions, making product protection a premium asset.”

The SteriDrop tube is capable of containing volumes up to 30 mL, which can cover three months’ supply of daily eye treatment.

Source: Neopac

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content